Fulltext

Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths

Van Kriekinge G 1 , Castellsagué X 2 , Cibula D 3 , Demarteau N 4

Affiliations 

  • 1 Health Economics, GlaxoSmithKline Vaccines, Avenue Fleming, 20, Wavre, 1300, Belgium. Electronic address: georges.m.van-kriekinge@gsk.com
  • 2 Cancer Epidemiology Research Program, Institut Català d'Oncologia (ICO)-IDIBELL, CIBERESP, L'Hospitalet de Llobregat, Catalonia, Spain
  • 3 Gynecologic Oncology Centre, General University Hospital of the First Medical School, Charles University, Prague, Czech Republic
  • 4 Health Economics, GlaxoSmithKline Vaccines, Avenue Fleming, 20, Wavre, 1300, Belgium
Vaccine, 2014 Feb 3;32(6):733-9.
PMID: 24291200 DOI: 10.1016/j.vaccine.2013.11.049

Abstract

Human papillomavirus (HPV) vaccination offers potential for primary prevention of HPV-related pre-cancers and cancers as demonstrated in clinical trials. Mathematical models have estimated the potential real-life impact of vaccination on the burden of cervical cancer (CC). However, these are restricted to evaluations in a limited number of countries.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications